|
F.G. Ivanova, T.I. Nikolaeva, N.I. Spiridonova, L.N. Afanasyeva, P.V. Nikiforov, T.N. Zharnikova
Clinical experience with the use of combination drug therapy in the first line treatment of metastatic non-small cell lung cancer
|
№14 / 2023
|
|
O.O. Gordeeva, K.A. Ivanova, A.A. Meshcheryakov
Ceritinib in the treatment of ALK-positive non-small cell lung cancer
|
№11 / 2023
|
|
O.O. Gordeeva, N.A. Meshcheryakova, A.A. Meshcheryakov
Lorlatinib in the treatment of ALK-positive non-small cell lung cancer
|
№6-7 / 2023
|
|
A.I. Semenova (1), S.A. Protsenko (1), G.M. Teletaeva (1), D.Kh. Latipova (1), A.V. Novik (1, 2)
Neoadjuvant immunotherapy for non-small cell lung cancer
|
№11 / 2021
|
|
F.V. Moiseenko (1, 2)
Hope or error: can combinations of EGFR tyrosine kinase inhibitors and other drugs replace monotherapy?
|
№11 / 2021
|
|
E.V. Artemieva (1), F.V. Moiseenko (1, 2, 3), N.M. Volkov (1), V.V. Egorenkov (1), N.Kh. Abduloeva (1), A.A. Bogdanov (1), A.S. Zhabina (1, 2), N.V. Levchenko (1), V.M. Moiseenko (1)
Effectiveness of a shortened cycle of monoimmunotherapy in non-small cell lung cancer
|
№7 / 2021
|
|
F.V. Moiseenko, A.A. Kudryavtsev, A.V. Myslik, N.M. Volkov
NEW MOLECULAR SUBTYPES OF NON-SMALL CELL LUNG CANCER AND THE POSSIBILITIES OF THEIR TREATMENT
|
№17 / 2017
|
|
S.L. Gutorov, E.I. Borisova, M.E. Abramov, A.N. Lud, E.A. Arutyunyan
NON-SMALL LUNG CANCER. EXPANDING THERAPEUTIC OPPORTUNITIES: PEMBROLIZUMAB IN A NUMBER OF MALIGNANT TUMORS
|
№8 / 2017
|
|
Yu.A. Ragulin
NEOADYAVANT THERAPY OF NON-SMALL CELL LUNG CANCER: ARE THERE ANY PERSPECTIVES?
|
№8 / 2017
|
|
A.V. Smolin (1), E.V. Kryukov (1), A.V. Konev (1), S.N. Nikolaeva (1), Yu.E. Shamanskaya (1), A.V. Gorbacheva (2), A.G. Matveev (1)
OPTIMIZATION OF TREATMENT TACTICS USING TARGETED THERAPY IN METASTATIC AND LOCALLY ADVANCED SMALL CELL LUNG CANCER
|
№17 / 2016
|
|
E.I. Borisova, S.L. Gutorov, M.E. Abramov
TREATMENT OF NON-SMALL CELL LUNG CANCER: THE NEXT STEP
|
№17 / 2016
|
|
A.I. Semenova, S.A. Protsenko, A.V. Novik, D.H. Latipova, G.M. Teletayeva, T.Y. Semiglazova
ROLE OF NEW ANTIANGIOGENIC DRUGS IN THE SECOND-LINE TREATMENT OF NON-SMALL-CELL LUNG CANCER
|
№17 / 2016
|
Русский
